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Platonia insignis fruit, popularly known as bacuri, is traditionally used in folk medicine for 
its anti-inflammatory and antioxidant properties. Therefore, this study determined the chemical 
composition and biological activities of the bacuri’s shell and seeds extracts, considered residues 
from its consumption and industrial uses. Four biflavonoids (GB-2a, GB-1a, morelloflavone, and 
volkensiflavone) were identified in the extracts by high-performance liquid chromatography-diode 
array detection (HPLC-DAD), liquid chromatography tandem mass spectrometry (LC-MS/MS), 
and liquid chromatography-solid phase extraction-nuclear magnetic resonance (LC-SPE-NMR) 
techniques. Morelloflavone was identified as the main compound in the shell ethyl acetate extract, 
being responsible for the high in vitro antioxidant (50% effective concentration (EC50) ranging 
from 8.0-10.5 µg mL−1 in different protocols), anti-glycant (80%), and moderate inhibition of nitric 
oxide (1.56 µg mL−1 for > 90% cell viability) activities. This extract showed promising in vivo 
anti-inflammatory activity evaluated through the paw edema protocol after its incorporation into a 
liquid-crystalline drug carrier system, reducing the edema by up to 31%. The results demonstrated 
the potential of the fruit for the development of drugs of natural origin and corroborated to add 
economic value to these discarded residues.
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Introduction
According to the World Health Organization (WHO), 
between 2000 and 2015, the world’s life expectancy has 
risen at five years, surpassing the 80 years’ mark in some 
countries. This current growth can be attributed mainly due 
to the advances in science and technology that have led to 
a significant improvement in the quality of life and disease 
prevention. In fact, there was a significant increase in the 
number of diseases, especially those related to common 
aging disorders, and as a reflection of this new reality, 
studies aiming the development of new drugs are being 
carried out all over the world.1 In this context, tropical fruits 
represent an original and valuable source for the discovery 
of new therapeutic agents since they may contain numerous 
pharmacologically active compounds and present potential 
for the development of new medicines.2
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The Platonia insignis Mart. species, popularly known 
as “bacurizeiro”, is an example of this potential still to be 
explored. This species belongs to the Clusiaceae family 
and is considered a large fruity tree, which is also used for 
wood extraction, being found predominantly in Brazilian 
northern and northeastern regions.3
The bacuri, P. insignis fruit, is very consumed by the 
population from the Amazon region, both in natura and in 
the manufacture of sweets, jams, and ice creams, presenting 
great importance to the local market. Morphologically, the 
fruit is a single-billed berry, is about 10 cm, 100 g, rounded, 
oval or flattened,4 and is composed by one to five seeds 
enveloped by the endocarp, the edible part, which represents 
only 3-4% of the total fruit mass. Therefore, it can be 
said that this fruit is, in mass, predominantly composed 
of shell and seed. Folk medicine describes the use of this 
species as healing, antimicrobial, antitumor, antioxidant 
and anti-inflammatory source,4,5 and for the treatment of 
skin diseases and diarrhea.6
The literature reports promising results of the extracts 
and isolated compounds of P. insignis, containing a range 
of biological activities, such as reduction of oxidative 
stress,7-9 enzymatic inhibition of α-glucosidase and 
acetylcholinesterase,10,11 immuno-modulatory effects 
and low in vivo toxicity.12 Bacuri’s seeds are rich sources 
of fatty acids, triacylglycerols and xanthones that 
exhibit antiepileptic and antiparasitic effects,13,14 and 
polyisoprenylated benzophenones, with vasorelaxant 
effect in animal models.15 The compounds 1,3-distearyl-
2-oleylglycerol (TG1), 2-oleyl-1,3-dipalmitoyl-glycerol 
(ODG) and garcinielliptone FC (GFC), and a polycyclic 
polyprenylated acylphloroglucinol were isolated from the 
hexane extract of P. insignis seeds. TG1 was effective in 
healing wounds in rats16 and ODG was evaluated regarding 
toxicological, mutagenic and antioxidant effects in vitro.9 
GFC presented antioxidant, vasorelaxant and antiparasitic 
activity.6,15,17 In a recent study18 of the hydroalcoholic 
extract of P. insignis, containing derivatives of the flavonoid 
glycosides quercetin and myricetin, showed potential 
antifungal activity against vaginal Candida species. 
Considering these previous reports, P. insignis has proven 
to be a valuable source of bioactive compounds.
Anti-inflammatory and antioxidant activities are 
widely explored in natural products chemistry, mainly due 
to their importance and benefic effects for humankind. In 
the past few years, there has been a considerable growth 
in the number of studies that proves that free radicals 
and other oxidizing compounds present key roles on 
the aging process and development, for example, of 
degenerative, cardiovascular and decline of the immune 
system diseases.19
In the search for novel alternatives for the inflammatory 
process treatment, natural products have also been 
highlighted as promising sources. Previous reports20 
evidence that a large variety of natural products (such as 
terpenes, alkaloids, tannins, lignans, saponins, coumarins, 
and flavonoids) can inhibit the synthesis of inflammation 
chemical mediators. Ethnopharmacological studies21 also 
highlight this potential, since teas and infusions prepared in 
various regions of the globe present positive results when 
scientifically tested.
For these and other activities that present, indeed, effects 
on the organism, it is important to insert the active sample 
into carrier systems. This type of system can protect the 
compounds from chemical and physical degradations and, 
additionally, ensures the performance at the correct time 
and place. Liquid crystalline systems (LCS) are examples 
of such carrier systems which can be used as drug delivery 
system since they can moderate the release of compounds 
incorporated therein.22 This feature is a result of its large 
internal interfacial area, with different physicochemical 
characteristics of the external area, which creates two 
environments with different properties in the formulation, 
allowing the compartmentalization of both polar and 
nonpolar drugs.23
The search for drug carrier systems that can be used 
as a vehicle for bioactive molecules is an innovative 
approach within the chemistry of natural products. 
Therefore, considering that the shell and seeds from 
Platonia insignis Mart. fruits are mainly discarded, this study 
aimed to identify the bioactive compounds in these residues, 
which could lead to the reuse of the biomass generated and 
add commercial value to it. For that, the extracts obtained 
were evaluated for in vitro antioxidant, anti-glycation, and 
inhibition of NO activities. Additionally, the in vivo evaluation 
of the ethyl acetate (EtOAc) shell extract incorporated into a 
liquid crystalline system was performed for the paw edema 
protocol. The bioactive compounds were determined in 
the extracts by different phytochemical analyses, such as 
high performance liquid chromatography tandem mass 
spectrometry (HPLC-MS/MS), high performance liquid 
chromatography-solid phase extraction-nuclear magnetic 
resonance (HPLC-SPE-NMR). The major compound 
of EtOAc shell extract, morelloflavone, was isolated to 
unequivocally determine its structure by NMR technique.
Experimental
Plant material
The Platonia insignis Mart. fruits were commercially 
acquired in São Luiz, at the Brazilian state of Maranhão 
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in March 2014. The fruits were stored at −40 °C until the 
beginning of this study. The authorization for studying this 
fruit was conceded by the National System for Management 
of Genetic Heritage and Associated Traditional Knowledge 
(SisGen), No. A67DE7A.
Extract preparation
Fruits were separated into shell, seeds, and pulp. Shell 
(280.1 g) and seeds (104.5 g) were dried at 40 °C in a 
circulating air oven and pulverized in liquid nitrogen by a 
mechanical grinder, while the pulp was discarded. Dried 
and pulverized material were individually extracted by 
maceration sequentially with hexane, ethyl acetate, and 
methanol (98%, Êxodo Científica, Sumaré, Brazil), for 
24 h in each solvent. The supernatants were concentrated 
to dryness using a rotatory evaporator at 40 °C and 
then lyophilized to remove any water residue, yielding 
n-hexane (6.78 and 50.44 g), EtOAc (5.87 and 32.51 g), 
and MeOH (47.06 and 7.36 g) extracts for the shell and 
seeds, respectively.
Chromatographic procedures
High performance liquid chromatography-diode array 
detection (HPLC-DAD)
Analytical HPLC analyses were performed on an 
HPLC-DAD Prominence Shimadzu®, equipped with 
LC-10AD pump, DGU 20-A3R degassing unit, SPD-M10A 
diode array detector, SIL-10AF automatic injector, and 
CBM-20A communication module. A Phenomenex® 
C18-Luna column (250 × 4.6 mm internal diameter (i.d.), 
5 µm) was employed, and the mobile phase consisted in 
the solvent system H2O (A) and MeOH (B) (HPLC grade, 
J.T. Baker-Avantor, Radnor, USA), 1.0 mL min−1 flow 
rate, 25 °C, and 20 µL injection volume. The dried extracts 
(seeds and shell extracted with EtOAc and MeOH) were 
solubilized in MeOH:H2O (8:2, v/v) at a concentration 
of 10 mg mL−1, passed through an SPE C18 cartridge for 
clean-up procedure and filtered in 0.22 µm membrane. The 
gradient employed for the initial analyses consisted of a 
gradient from 5 to 100% B in 60 min, and chromatograms 
were registered in the wavelength range of 200-400 nm.
HPLC-MS/MS analysis
The EtOAc extracts were analyzed in an HPLC 
Prominence Shimadzu® coupled to a mass spectrometer 
amaZon SL Bruker Daltonics®. The HPLC consisted of 
an LC-20AD pump, DGU 20-A3R online degassing unit, 
SPD-M20A diode array detector, CTO-20A column 
oven, SIL-20AHT automatic injector, and CBM-20 
communication module. A Phenomenex® C18-Luna 
column (250 × 4.6 mm i.d., 5 µm) was used, and the 
solvent system consisted of H2O (A) and MeOH (B), both 
acidified with 0.1% v/v formic acid, at 1.0 mL min−1 flow 
rate, 25 °C and 2 µL injection volume. The dried extracts 
were solubilized in MeOH:H2O (8:2, v/v) at a concentration 
of 1.0 mg mL−1, centrifuged for 3 min at 4500 × g and 
supernatants were analyzed. The optimized separation 
conditions employed for the analyses consisted of a linear 
gradient from 5 to 100% B in 60 min for the shell and a 
linear gradient from 5 to 30% B in 25 min, followed by 30% 
B until 75 min for the seeds extracts. The mass spectra were 
obtained separately in both positive and negative mode, in 
a mass range of 50-1200 Da and applying auto-MSn (n = 3) 
mode. The mass spectrometer source parameters were set 
as follows: capillary voltage at 4.5 V, nitrogen used as the 
nebulizing and drying gas (50 psi, 10 L min−1, 300 °C). 
The data was processed through Bruker Compass Data 
Analysis 4.3® software.
Semi-preparative HPLC-DAD fractionation of the EtOAc 
shell crude extract
A portion (160 mg) of the EtOAc extract from P. insignis 
shell was fractionated by an HPLC-DAD Prominence 
Shimadzu®, equipped with LC-6AD pump, DGU 20-A5R 
degassing unit, SPD-M20A diode array detector, and 
CBM-20A communication module. A semi-preparative 
Phenomenex® C18-Luna column (150 × 21.2 mm i.d.; 
5 µm) was employed in this chromatographic step, and 
the solvent system consisted in H2O (A) and MeOH (B), 
isocratic mode 60% B in 30 min, a flow rate of 10 mL min−1 
and injection volume of 1 mL. After collection, the major 
compound was concentrated in a rotatory evaporator, 
yielding 5.0 mg of morelloflavone (2).
LC-SPE-NMR fractionation of the EtOAc seeds extract
The seeds EtOAc extract was submitted to an 
LC-SPE-NMR fractionation to confirm the information 
proposed by LC-MS/MS analysis. An Agilent 1260 Infinity 
system equipped with a quaternary pump, auto-sampler 
ALS, and diode array detector (DAD VL), connected to 
a Bruker Spark Prospekt II solid-phase extraction system 
using 2 mm Hyspher resin (GP, polydivinyl benzene, 
particle 5-15 µm) cartridge to peak collection was used. 
A Phenomenex® C18-Luna column (250 × 4.6 mm i.d., 
5 µm) was employed, and the mobile phase consisted of the 
solvent system H2O (A) and MeOH (B), 1.2 mL min−1 flow 
rate and 25 °C. UV detection was performed at 254 nm. 
The extract was solubilized in MeOH:H2O (8:2, v/v) at a 
concentration of 20 mg mL−1, passed through an SPE C18 
cartridge for clean-up procedure and filtered in 0.22 µm 
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membrane. The separation was done using a linear gradient 
from 5 to 30% B in 25 min, followed by an isocratic mode 
at 30% B until 75 min. NMR samples were prepared by 
a Gilson Liquid Handler 215. Then, 20 µL of the sample 
at 20 mg mL−1 was injected 15 times, and the peaks of 
interest were collected using the multitrapping function 
considering the peaks retention time: 39.00-40.10 min 
for compound 1, 40.80-42.20 min for compound 2, 
53.22-55.22 min for compound 3 and 56.00-58.00 min 
for compound 4. After completing the analyses, the 
loaded SPE cartridges were dried with N2 gas, and the 
adsorbed compounds were eluted using methanol-d4 
(99.8% D, Sigma-Aldrich, St. Louis, USA) into 3 mm 
NMR tubes. NMR spectra were recorded on the NMR 
spectrometer described later, with double solvent pre-
saturation suppressing any residual water and methanol 
signals (pulse program “lc1pnf2”). HyStar software was 
used for automated trapping control.
Morelloflavone quantification and method validation
To validate the HPLC-DAD method, the parameters 
of linearity, precision (intra and inter-day repeatability), 
limit of detection, limit of quantification, and robustness 
were evaluated according to the method described by 
International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use (ICH).24 
To obtain the analytical curve and linearity study, standard 
solutions of the previously isolated morelloflavone 
were used in the concentration range between 0.01 and 
0.20 mg mL−1, diluted from a 1 mg mL−1 stock solution. 
Precision was expressed by the standard deviation of 
three consecutive injections of the 0.1 mg mL−1 standard 
solution on three different days. The limits of detection and 
quantification were calculated considering, respectively, 
3.3 and 10 times the ratio between the standard deviation 
of the linear coefficient (s) and the angular coefficient (S) 
of the analytical curve.
The method robustness was expressed by the coefficient 
of variation of three consecutive injections of the 
0.1 mg mL−1 standard solution and evaluated changing 
the mobile flow rate from 1.0 to 0.8 mL min−1. For 
morelloflavone quantification in the ethyl acetate extract 
of P. insignis shell, 2.5 mg of extract was solubilized in 
1 mL of MeOH:H2O (8:2, v/v). Prior to HPLC injection, 
the extract was passed through the clean-up procedure in 
C18 cartridge, as previously described. The extract and 
calibration curve analyses were performed in triplicate.
NMR analyses
The 1H (600 MHz), 13C (125 MHz), correlation 
spectroscopy (COSY), heteronuclear single quantum 
correlation (HSQC), and heteronuclear multiple bond 
correlation (HMBC) NMR spectra were recorded on 
a Bruker Avance III HD 600 MHz NMR spectrometer 
equipped with a Triple Inverse TCI 5 mm Cryo-probehead 
and automated sample changer SampleXpress. Spectra 
were calibrated considering the residual solvent signals 
(dimethyl sulfoxide (DMSO-d6): d 2.50 and 39.5; 
CD3OD-d4: d 3.31 and 49.00; for 1H and 13C, respectively), 
and tetramethylsilane (TMS) as an internal standard. Both 
DMSO-d6 and CD3OD-d4 were acquired from Sigma-




The DPPH• (2,2-diphenyl-1-picrylhydrazyl) scavenging 
activity was employed to determine the extracts possibility 
to reduce this radical, by applying the method previously 
described.25 Dried extracts were solubilized in EtOH at 
4 mg mL−1 (EtOH 99%, Sigma-Aldrich, St. Louis, USA) 
and diluted to obtain various concentrations ranging 
from 0.4 to 100 µg mL−1. The assays were performed by 
adding 35 µL of the samples in 215 µL of an ethanolic 
solution of DPPH (100 µmol L−1). EtOH was used as 
negative control and rutin was used as standard. After 
30 min incubation in the dark, the activity was determined 
spectrophotometrically at 517 nm in a microplate reader 
(Synergy2 Multi-Mode, BioTek, Winooski, VT, USA). 
The DPPH• scavenging activity was calculated following 
the equation DPPH•scavenging(%) = [(Abs517nm(control) – 
Abs517nm(sample)) / Abs517nm(control)] × 100, where 
Abs517nm(control) and Abs517nm(sample) are the absorbances 
at 517 nm of the control and sample, respectively. The 
radical scavenging capacity was expressed in EC50 (50% 
effective concentration), which was calculated graphically 
using the analytical curve in the linear range.
ABTS•+ scavenging capacity
The ABTS•+ [2,20-azino-bis(3-ethylbenzothiazoline-
6-sulfonic acid)] cation radical scavenging capacity was 
determined based on a method described by Fraige et al.25 
Initially, 1 mL of an ABTS solution at 10 mmol L−1 
was mixed with 430 µL of ammonium persulfate 
(8.17 mmol L−1). The cation radical was obtained after 
holding this mixture in the dark at room temperature for 
16 h, and this solution was diluted 60 times. Samples 
were prepared in concentrations ranging from 0.4 to 
100 µg mL−1, and 35 µL of these solutions were added to 
215 µL of ABTS•+ solution. EtOH was used as negative 
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control and quercetin was used as standard. The mixture 
was incubated in the dark for 30 min and the activity 
was determined spectrophotometrically at 755 nm in 
a microplate reader (Synergy2 Multi-Mode, BioTek, 
Winooski, VT, USA). The ABTS•+ scavenging activity was 
calculated by the following equation: ABTS•+scavenging(%) = 
[(Abs755nm(control) – Abs755nm(sample)) / Abs755nm(control)] 
× 100. The radical scavenging capacity was expressed in 
terms of EC50, which was calculated graphically using the 
analytical curve in the linear range.
Peroxyl radical scavenging capacity
The peroxyl radical (ROO•) scavenging assay 
was performed based on the fluorescence decay of 
pyranine (8-hydroxypyrene-1,3,6-trisulfonic acid 
trisodium salt, a fluorescent probe) when oxidized by 
peroxyl radicals originated from AAPH [2,20-azobis 
(2-methylpropionamidine)].25 The experiments were 
performed by adding 12.5 µL of sample solutions in ethanol 
(ranging from 0.4 to 100 µg mL−1) and 62.5 µL of AAPH in 
phosphate-buffered saline (PBS) medium (40 µmol L−1) to 
75 µL of pyranin (10 µmol L−1), also in PBS. The pyranine 
fluorescence decay was measured at 37 °C for 90 min 
using a plate spectrometer at 485 nm (λexcitation) and 528 nm 
(λemission). Pyranine with AAPH (control 1) and without 
AAPH (control 2) were used as controls, and gallic acid 
was used as standard. The EC50 calculation was performed 
using the equation: radical scavenged(%) = [(Sample Area − 
Control Area 2) / (Control Area 1 − Control Area 2)] × 100.
Anti-glycation activity
The anti-glycation activity assay was performed using 
the bovine albumin (BSA) and methylglyoxal (MGO) 
method, as described by Lunceford and Gugliucci,26 with 
some modifications.25 A solution of BSA (1 mg mL−1) 
in phosphate buffer (10 mg mL−1, pH 7.4) containing 
150 mmol L−1 NaCl was initially prepared. The MGO 
(5 mmol L−1) and the EtOAc and MeOH extracts 
(solubilized in 1:1 DMSO:H2O to reach 150 µg mL−1) 
were added to the BSA solution and then incubated for 
72 h at 37 ° C under 150 rpm shaking. Aminoguanidine 
(10 mmol L−1) was used as standard and the samples 
were incubated in the presence and absence of MGO to 
have the intrinsic fluorescence of each sample. After the 
incubation period, the fluorescence of the samples was 
measured using a plate spectrometer at 370 nm (λexcitation) 
and 440 nm (λemission). For the calculation of inhibition, the 
equation was used: Inhibition of AGEs formation(%) = 
[(FLCN − FLbCN) − (FLS − FLbS)] / (FLCN − FLbCN); where 
FLCN and FLbCN are the fluorescence intensities of the 
negative control mixture and its blank, respectively; and 
FLS and FLbS are the fluorescence intensities of the extract 
and its blank, respectively.
In vitro inhibition of NO production assay
Cell culture
The cell line RAW 264.7, derived from a leukemic 
mouse monocyte-macrophage line American Type Culture 
Collection (ATCC)/TIB-71, was acquired from the Rio de 
Janeiro Cell Bank (BCRJ). Cells were maintained at 37 °C 
in a humidified incubator with 5.0% CO2, in cells culture 
flasks in Dulbecco’s modified Eagle medium (DMEM, 
Lonza, Basel, Switzerland), using as supplements 10% of 
heat-inactivated fetal bovine serum (FBS, Gibco, Waltham, 
USA) and gentamicin (1:1000, Gibco, Waltham, USA).
Cytotoxicity assay
Cells were initially seeded in 96-well plates 
(1 × 105 well−1) in a final volume of 200 µL and incubated 
for 18 h. After this time, the medium was removed, cells 
were treated during 90 min with the EtOAc shell extract of 
P. insignis (solubilized in DMSO and diluted with DMEM 
to reach concentrations from 0.78 to 25.0 µg mL−1), and 
then incubated with lipopolysaccharide (LPS, 100 ng mL−1, 
Sigma-Aldrich, St. Louis, USA) under 5.0% of CO2 for 18 h 
at 37 °C. Cytotoxic activity was determined by the MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide) method, in which the new supernatant was 
collected for NO determination, and the macrophages were 
incubated with MTT at 5 mg mL−1 in PBS for 3 h at 37 °C. 
Sodium dodecyl sulfate (SDS 20%, 0.01 mol L−1 HCl) was 
added to dissolve formazan crystals and then absorbance 
was measured at 595 nm (BioTek-Synergy H1).
Quantification of nitrite
The measurement of the nitrite concentration was 
performed by the Griess method from cell culture 
supernatant, in which 100 µL of a solution consisting of 
0.1% NEED (naphthyl-ethylenediamine dihydrochloride) 
solution and 1% sulfanilamide in H3PO4 (v/v), both 
from Sigma-Aldrich (St. Louis, USA), were mixed to 
100 µL of cell supernatant, and the nitrite concentration 
was determined by measuring the absorbance at 540 nm 
(BioTek-Synergy H1), limit of detection of 0.06 to 200 µM.
Preparation and polarized light microscopy analysis of the 
liquid crystalline system
The liquid crystalline system used to incorporate the 
EtOAc extract of the shell to perform the in vivo anti-
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inflammatory was a liquid crystalline system prepared 
from one of the points in the ternary diagram obtained 
previously.27,28 This LCS was composed of 40% oleic acid 
as oily phase, 30% Procetyl® as the surfactant, and 30% 
high-purity water as the aqueous phase. EtOAc extract 
was loaded into the oily phase, reaching 4 mg of extract 
per 10 g of LCS.
The unloaded and EtOAc extract-loaded LCSs were 
analyzed by polarized light microscopy (PLM) using a 
Motic® Type 102M Optical Microscope (Motic®, Xiamen, 
Fujian, China) optical microscope by placing a drop of each 
formulation under a coverslip. The analysis was performed 
at room temperature (25 °C) and images were acquired at 
40× magnification.
In vivo anti-inflammatory assay
The in vivo study was carried out after the Committee 
on Ethics in the Use of Animals (CEUA) approval in the 
Faculty of Pharmaceutical Sciences of Araraquara, Unesp 
(Protocol No. 18/2017). The paw edema protocol described 
by Vinegar et al.29 was used, which proposes the induction 
of paw edema in the animal using dexamethasone as a 
drug and evaluation of the decrease of this process after 
the administration of the samples analyzed. Male mice of 
Swiss lineage with a mean weight of 35 g were subdivided 
into seven groups, with seven animals per group: 
group I: untreated (negative control); group II: treated 
with topic dexamethasone at 1 mg g−1 (positive control); 
group III: treated only with P. insignis EtOAc shell extract 
(400 µg mL−1) solubilized in EtOH:H2O 95:5 (v/v); group 
IV: treated with formulation 1 (F1), at 400 µg g−1, LCS 
without extract; group V: treated with P. insignis EtOAc 
shell extract incorporated in formulation F1 at 400 µg g−1; 
group VI: treated with formulation 2 (F2), a carboxymethyl 
cellulose (CMC) gel without extract; and group VII: 
treated with P. insignis EtOAc shell extract incorporated 
in formulation F2 at 400 µg g−1. F1 formulation refers to 
the drug carrier system developed for the incorporation 
of the fruit shell EtOAc extract, while F2 formulation is 
a commonly used gel consisting of H2O:EtOH 95:5 (v/v) 
mixture and 2% (m/m) carboxymethylcellulose.
The paw edema was induced by intraplantar injection 
of 100 µL of 1% (m/m) λ-carrageenan into the mouse’s 
paw. One hour later, dexamethasone or test formulations 
(100 mg) were applied to the animal’s paw, and after 4 and 
6 h of λ-carrageenan administration, the leg thickness was 
measured (in mm) using a digital micrometer. The percent 
inhibition of paw edema was calculated according to the 
equation: Inhibition(%) = (Ec − Et) / Et × 100, in which Ec 
is the paw edema of the control group and Et is the edema 
of the treated group. The mean and standard deviation of 
the thickness were calculated for each group. The two-way 
analysis of variance (ANOVA) was performed, followed by 
Tukey’s post-test. The difference between the mean edema 
of the treated animals and the control group was considered 
significant at p < 0.05.
Results and Discussion
Chromatographic investigation of the extracts
The extraction procedure followed (using solvents with 
different polarities) was chosen to ensure the extraction of 
compounds with a wide range of polarities. This procedure 
would already result in a preliminary separation of these 
compounds by the different solvents used. Ethyl acetate 
(EtOAc) and methanolic (MeOH) extracts obtained from 
P. insignis shell and seeds were analyzed by HPLC-DAD 
for a preliminary chemical investigation using optimized 
chromatographic methods, which chromatograms are 
shown in the Supplementary Information (SI, Figure S1).
Shell
The chromatograms obtained for the EtOAc shell 
extract indicated a selective extraction of a specific 
compound. This extract was then subjected to semi-
preparative chromatography for isolation of the major 
compound, yielding compound 2. This compound was 
identified as morelloflavone (Figure 1) by the comparison 
with data of literature30,31 of 1D and 2D NMR analyses and 
fragmentation pattern by LC-MS/MS (SI section).
The assignments of the main 1H and 13C NMR chemical 
shifts of compound 2 (2a + 2b rotamers), in CD3OD-d4, 
were achieved with the assistance of gHSQC and gHMBC 
experiments (NMR spectra can be found in the SI section, 
Figures S2-S4) and are shown in the Table S1 (SI section). 
Although long-range heteronuclear correlations were not 
observed between H-2 or H-3 with C-8”, partly due to the 
pre-saturation of the water signal which resulted in the 
concomitant irradiation of H-3, the signals attributed to 
C-8” (d 102.0 in both rotamers) evidenced that the flavonoid 
units were linked through C-3 and C-8”. Further evidence 
for the chemical structure established for 2 was provided by 
the molar ratio (1:0.35) observed between the rotamers 2a 
and 2b.32 The relative configuration of 2 was determined as 
shown in Figure 1, based mainly on the diaxial coupling 
constant value (J ca. 12 Hz) between H-2 and H-3, which 
was observed when 2 was analyzed in DMSO-d6.
Morelloflavone is a biflavonoid commonly found in 
Garcinia species (also from the Clusiaceae family).33 Many 
studies regarding this compound have revealed important 
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bioactivities such as tyrosinase inhibitor,30 proteasome-
inhibitory activity,34 promotion of secretory phospholipase 
A2 (PLA2) inhibition,35 anti-inflammatory,35 activity against 
low density lipoprotein (LDL) peroxidation,36 antitumor-
promoting activity,37,38 and potent and selective anti-HIV 
(human immunodeficiency virus) activity.39
Morelloflavone (96% purity, estimated by HPLC-DAD) 
was quantified in P. insignis EtOAc shell extract and the 
developed method showed to be linear in the concentration 
range from 0.01 to 0.20 mg mL−1, presenting a coefficient of 
correlation (r2) of 0.9937. For the precision determination, 
the values for intra-day and between 3 different days 
(inter-day) repeatabilities were calculated for the retention 
time and peak area at the 0.1 mg mL−1 concentration and 
were expressed by the coefficient of variation (CV, in %). 
Considering each day repeatability, the CV ranged from 
0.92 to 2.16% for the retention time and from 1.17 to 
7.72% for peak area; for the inter-day repeatability, these 
values were 2.97 and 4.37% for retention time and peak 
area, respectively.
The method robustness was evaluated by changing 
the mobile flow rate from 1.0 to 0.8 mL min−1, and the 
coefficient of variation for retention time and peak area 
was 0.33 and 0.39%, respectively; therefore, the method 
can be considered accurate and robust.
The limits of detection and quantification were, 
respectively, 0.01 and 0.04 mg mL−1. The morelloflavone 
concentration found by the analytical curve in the EtOAc 
extract was 0.085 ± 0.006 mg mL−1 (CV = 6.96%), which 
consists of 340 mg g−1 of the extract. This result shows 
that bacuri is a very important source of morelloflavone.
Seeds
To also investigate the seeds extract, LC-MS/MS analyses 
were also performed to identify the chemical compounds 
present in this extract (Figure 1). Figure 2 presents the 
base peak chromatogram (BPC) obtained for the EtOAc 
seeds extract in negative mode, and the peaks identified 
are described in Table 1. The compounds’ identification 
was based on the deprotonated molecules, fragmentation 
patterns, and comparison with data from the literature.40 The 
MS2 and MS3 spectra described in Table 1 can also be found 
in Figures S5-S8 (SI section), and the proposed fragments 
Figure 1. Main compounds identified in P. insignis EtOAc extracts: 
(1) GB-2a; (2) morelloflavone; (3) GB-1a; (4) volkensiflavone. 
Morelloflavone was isolated from the P. insignis shell EtOAc extract, and 
its relative stereochemistry was determined by NMR.
Figure 2. Base peak chromatogram (BPC) of the P. insignis EtOAc seeds extract. Peak numbers are identified in Table 1. Experimental conditions are 
described in the Experimental section.
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formed in this analysis can be found in Figure S9 (SI section). 
Additionally, the UV spectra obtained for each compound 
is shown in Figure S10 (SI section).
The major compounds (1 and 3, GB-2a and GB-1a) 
presented a very similar fragmentation pattern. Peaks of 
compounds 1 (at m/z 557 [M − H]–) and 3 (at m/z 541 
[M − H]–) formed the major MS2 fragments at m/z 431 and 
415, respectively, consistent with the loss of a C6H6O3 group 
(126 Da) resulted from the biflavonoid C ring cleavage. The 
MS3 fragment observed at m/z 295 could be related to the 
loss of a C8H8O2 group (136 Da) by a retro Diels-Alder C 
ring-opening reaction. Additionally, an MS3 fragment at 
m/z 321 was observed for both compounds, which could 
be explained by the B ring flavonoid cleavage, resulting in 
the loss of a C6H6O2 group (110 Da) for compound 1, and 
C6H6O (94 Da) for compound 3.
Peaks of compounds 2 (at m/z 555) and 4 (at m/z 539) 
could be identified as the minor compounds in this extract: 
morelloflavone and volkensiflavone, respectively. For both 
compounds, a loss of a C6H6O3 group (126 Da) from the 
biflavonoid C ring cleavage was observed, forming the 
fragments at m/z 429 for compound 2 and m/z 413 for 
compound 4. The MS3 spectra also revealed the CO loss 
(28 Da) and retro-Diels-Alder C ring-opening reaction, 
forming MS3 ions at m/z 401 and 295 for morelloflavone, 
and m/z 385 and 279 for volkensiflavone.
Considering that the attempts to isolate the compounds 
present in the seeds were unsuccessful since the peaks 
coeluted and the time of the analysis would be very long 
for isolation purposes, a micro-fractionation was performed 
by LC-SPE-NMR approach to confirm the compounds 
proposed by LC-MS/MS. The procedure consisted of a 
fractionation performed in the analytical scale in which 
SPE collectors are connected to the chromatograph.
The obtained chromatogram is shown at the 
Supplementary Information (Figure S11). Each one 
of the four peaks were collected in micro SPE C18 
cartridges, which provided enough mass to perform 
1H NMR experiments (Figures S12 and S13, SI section). 
Bidimensional experiments were not possible to obtain due 
to the low mass amount collected.
The 1H NMR spectrum of 4 resembled the one obtained 
from 2 (isolated from bacuri’s shell), the only significant 
difference being the absence of the signals assigned to 
H-2”’ (2a: d 7.35 d, J 1.7 Hz, 1H), H-5”’ (2a: d 6.93 d, 
J 8.4 Hz, 1H), and H-6”’ (2a: d 7.30 d, J 8.4 and 1.7 Hz, 
1H) of 2, which were replaced by two doublets at d 7.75 
(J 8.4 Hz, 2H) and 6.94 (J 8.4 Hz, 2H), a characteristic 
of the apigenin subunit. Similarly, compound 4 has also 
been shown to be a mixture of rotamers, as evidenced 
by the signal at d 7.61 (d, J 8.5 Hz). Based mainly on 
this comparative analysis and comparison with the 
literature,32,41 an interflavonoid linkage C-3 → C8” was 
also suggested to occur in 4. This inference was supported 
by the mass fragmentation pattern observed for 4, and 
therefore it was identified as volkensiflavone.
1H NMR spectrometric data corroborated with the 
proposed chemical structures for 1 and 3 based on MS/MS 
analyses. Both 1H NMR spectra showed two sets of signals 
between 7.2-6.6 ppm and 6.0-5.1 ppm, whose values of 
chemical shifts were compatible with those previously 
reported for GB-1a and GB-2a.41 In these same spectra, 
signals between 3.0-2.4 ppm were present as well, thus 
reinforcing the flavanone nature of the structural subunits 
of 1 and 3, also proposed by MS/MS analyses.
Bioassays results
Antioxidant assays
All extracts obtained were evaluated regarding 
their antioxidant capacity using three different in vitro 
scavenging assays (DPPH•, ABTS•+ and ROO•) to observe 
the antioxidant capacities in different conditions. The EC50 
results obtained for each assay are shown in Table 2. DPPH• 
and ABTS•+ assays are based on an electron transfer causing 
the reduction of a colored oxidant agent in the organic and 
aqueous medium, respectively, and the ROO• assay is based 
on a hydrogen atom transfer in which there is a competition 
Table 1. Peak number according to Figure 2, retention time (tR), [M − H]– ion, MSn fragments, and compounds tentatively identified from the P. insignis 
EtOAc seeds extract
Peak tR / min [M − H]– MSn fragments / % abundance Compound
1 41.5 557
MS2 (557): 451 (2), 431 (100) 
MS3 (557 → 431): 321 (8), 295 (100) GB-2a
2 43.0 555
MS2 (555): 403 (3), 429 (100) 
MS3 (555 → 429): 429 (100), 401 (13), 357 (4), 295 (4) morelloflavone
3 57.5 541
MS2 (541): 447 (20), 415 (100) 
MS3 (541 → 415): 321 (40), 295 (100) GB-1a
4 59.9 539
MS2 (539): 445 (20), 433 (20), 413 (100) 
MS3 (539 → 413): 413 (100), 385 (40), 295 (1) volkensiflavone
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between antioxidants agents and substrates for the peroxyl 
radicals thermally formed.42
The results obtained evidenced that all P. insignis 
hexane extracts were not able to scavenge the free radicals 
formed in these assays, presenting a very elevated EC50 
value, which could be attributed to the high content of non-
polar compounds present in these extracts. For this reason, 
the hexane extracts were not chemically investigated. 
The methanolic extracts obtained from bacuri’s shell also 
presented elevated EC50 values, indicating that even though 
polar compounds were extracted, a high amount of sugars 
could have also been extracted employing this organic 
solvent. For the seeds methanolic extracts, EC50 values 
ranging from > 100 to 76 µg mL−1 were obtained, showing 
low antioxidant activities, probably also due to the presence 
of sugars. The ethyl acetate extracts obtained from the shell 
extract exhibited high antioxidant activities, with low EC50 
values of 10.5, 8.1 and 8.0 µg mL−1 for the DPPH•, ABTS•+ 
and ROO• assays, respectively, comparable to the standards 
used in this research. For the seeds ethyl acetate extracts, 
the peroxyl radical assay did not show antioxidant activity, 
while for the DPPH• and ABTS•+ methods, moderate 
activities were observed.
Antioxidant activities regarding P. insignis fruit extracts 
have already been described before for its pulp11 and 
seeds,14 whose activities were attributed to the presence 
of phenolic compounds. Costa Junior et al.14 reported that 
ethyl acetate and dichloromethane fractions from P. insignis 
seeds present antioxidant activity in vitro (measured by 
ABTS•+ and DPPH• assays), and in vivo (measured by 
protective effects against the cytotoxicity induced by H2O2 
in S. cerevisiae strains). In addition to the polyphenols, they 
attributed the high antioxidant activity to the xanthones 
alpha- and gamma-mangostin present in these fractions.14 
Considering that the biflavonoid morelloflavone is the 
major compound present in P. insignis EtOAc shell extract, 
it was possible to attribute the antioxidant bioactivities 
observed to this compound, since reports for the high 
antioxidant activity of this biflavonoid has already been 
reported.43 The flavonoid class presents, in general, 
important antioxidant properties due to the delocalization 
of the free radical formed. The ethyl acetate seeds extract 
also presented considerable antioxidant activities, however, 
the lower activity when compared to the shell extract can 
be related to the presence of major compounds GB-1a 
and GB-2a, which do not present a double bond between 
atoms C2” and C3”, important for the stabilization of the 
free radicals formed.44
Anti-glycation assay
To evaluate the anti-glycation properties of the EtOAc 
and MeOH P. insignis extracts, their advanced glycation 
end products (AGEs) formation inhibition was determined 
using a BSA/MGO system, and the results are shown in the 
Supplementary Information (Figure S14) as the percentage 
of inhibition of the glycation reaction.
The EtOAc extract obtained from the shell inhibited 
about 80% of the AGEs formation during this assay at the 
concentration employed (150 µg mL−1). This high activity 
was expected since compounds with high antioxidant 
properties can present potentialized anti-glycant effects,26 
and correlations between phenolic compounds and anti-
glycation activity have already been reported.38 On the other 
hand, the seeds extract presented moderate to low anti-
Table 2. EC50 values obtained for the DPPH•, ABTS•+ and ROO• antioxidant activity assays of the P. insignis extracts and standard compounds
Assay Shell EC50 / (µg mL−1) Seed EC50 / (µg mL−1)
DPPH•
Hex > 100 Hex > 100
EtOAc 10.50 ± 0.03 EtOAc 33.03 ± 0.10
MeOH > 100 MeOH 78.00 ± 0.09
rutin 2.13 ± 0.03 rutin 2.98 ± 0.08
ABTS•+
Hex > 100 Hex > 100
EtOAc 8.10 ± 0.09 EtOAc 30.00 ± 0.12
MeOH > 100 MeOH 75.90 ± 0.03
quercetin 3.10 ± 0.03 quercetin 4.00 ± 0.10
ROO•
Hex > 100 Hex > 100
EtOAc 7.99 ± 0.09 EtOAc > 100
MeOH > 100 MeOH > 100
gallic acid 1.93 ± 0.03 gallic acid 2.15 ± 0.60
EC50: 50% effective concentration; DPPH•: 2,2-diphenyl-1-picrylhydrazyl; ABTS•+: 2,20-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid); ROO•: peroxyl 
radical.
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glycation activity, ranging from 26 to 39% AGEs formation 
inhibition at the concentration employed (150 µg mL−1).
Additionally, to the formation of free radicals, glycation 
reactions also occur naturally in the human body through 
the enzymatic addition of reducing sugars in proteins. 
The major problem associated with this phenomenon is 
the product generated, called AGEs, which are highly 
reactive and can lead to complex reactions of dehydration, 
oxidation, and fragmentation, which are very harmful to 
the human body.45 The formation of AGEs is associated 
with the pathogenic process of diabetes and skin aging. 
Anti-glycation results have already been described for 
Garcinia species (also from Clusiaceae family), such as 
Garcinia semseii, G. volkensii46 and G. mangostana,47 in 
which the activities could be related to the presence of 
benzophenones, biflavonoids, and xanthones in the extracts, 
respectively. Previous studies11 also demonstrate the high 
α‑glycosidase inhibitory capacity of the hydroalcoholic 
pulp extract of P. insignis, indicating this is a potential 
source of glucose-lowering compounds, which are 
important for the glycemic control in type 2 diabetes.
Considering that the major compound present in the 
most active extract is morelloflavone, it is most likely 
that the anti-glycant activity observed is related to the 
presence of this compound in the sample. Morelloflavone 
has already been described46 for many bioactivities, 
including anti-glycation activity. A subfraction of the ethyl 
acetate fraction of P. insignis containing a mixture of the 
biflavonoids volkensiflavone and morelloflavone showed 
promising results as an adjuvant in the antibiotic therapy 
of multidrug resistant S. aureus strains overexpressing 
efflux pumps.48
In vitro inhibitory effects on NO production
Considering the high antioxidant and anti-glycation 
activities observed for the EtOAc extract obtained from the 
shell of P. insignis fruit, and due to the extract simplicity 
(showing the selective extraction of morelloflavone), this 
extract was also evaluated for their inhibitory effects on 
NO production in LPS-activated RAW 264.7 macrophages.
Therefore, RAW 264.7 cells were treated with different 
extract concentrations (0.78-25.0 µg mL−1) for 90 min, 
in which only concentrations 0.78 and 1.56 µg mL−1 
were considered promising since they presented cell 
viability ≥ 90% (Figure 3a). The other concentrations 
tested were discarded due to the cytotoxic results that could 
provide false positives. Considering the low toxicity of 
these samples, RAW 264.7 macrophages were stimulated 
with an inflammatory compound, LPS (100 ng mL−1) for 
18 h, and the nitrite concentration was determined in cell 
supernatant by the Griess reagent.
As observed in Figure 3b, the incubation with LPS led 
to an increase in the NO2– production when compared to the 
cells cultured only with medium (negative control). There 
was no difference in nitrite production when compared to 
LPS-stimulated macrophages in the presence or absence 
of P. insignis EtOAc shell extract. The MTT viability test 
was calculated based on the viability found in cells treated 
with LPS as 100% (positive control).
Previous studies correlate morelloflavone (obtained 
from Garcinia genus) to anti-inflammatory activities, both 
by in vivo49 and in vitro approaches.50 However, as observed 
by these results, the samples were not able to reduce the 
NO production in cells.
Inflammation is a biological response of the immune 
system, and the inflammatory response is divided into 
three phases. The first phase, an acute, transient phase, 
is characterized by local vasodilatation and increased 
capillary permeability. The second phase, a sub-acute 
phase, is characterized by the infiltration of leukocytes 
and phagocytic cells. And the third and last phase, a 
chronic proliferative one, in which tissue degeneration and 
fibrosis occur. In the inflammatory process, many chemical 
mediators are divided into two groups: those that are derived 
from plasma and the ones derived from cells.51
In this study, the quantified NO (which is one of the 
chemical mediators, derived from cells) was analyzed. 
Then, although the samples were not able to reduce the 
production of NO, they might act as anti-inflammatory 
agents in other chemical mediators. Furthermore, 
occasionally, the in vitro assay results cannot be correlated 
with the in vivo assays as this experiment does not mimic 
the biological environment of an animal entirely.52
Figure 3. (a) Cytotoxicity evaluation of P. insignis EtOAc shell extract. 
The red line indicates 90% cell viability; (b) percentage of inhibition of 
nitrite (NO2–) production of EtOAc extract at the concentrations with cell 
viability ≥ 90%, determined by the Griess reagent. Results indicate the 
mean ± SD of three independent experiments performed in quadruplicate 
for each condition.
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Preparation and polarized light microscopy analysis of the 
liquid crystalline system
Due to the important biological activities presented 
by the in vitro assays for the P. insignis EtOAc shell 
extract and the almost exclusive presence of an interesting 
biflavonoid (morelloflavone), this extract was selected 
for the incorporation into the drug delivery system and 
analysis of its potential anti-inflammatory activity in vivo. 
The chosen drug delivery system was a liquid-crystalline 
system, which could be identified through polarized 
light microscopy, as observed in the Figure S15 (SI 
section). Structures in the form of stretch marks were 
observed, which are important features of the hexagonal 
liquid-crystalline mesophase chosen for the developed 
system.53 This type of mesophase is one of the most 
common in formulations of topical use due to the ability 
to protect the compounds incorporated from thermal and 
photodegradation, in addition to promoting the retention 
of water in the stratum corneum, which increases the skin 
permeation.54,55
In vivo anti-inflammatory assay
The carrageenan-induced paw edema in rats used 
in this in vivo anti-inflammatory assay releases various 
inflammatory mediators, and thus, this experiment was 
conducted to confirm if the P. insignis EtOAc extract 
present anti-inflammatory activity, considering the high 
amounts of morelloflavone extracted. The results obtained 
in the in vivo anti-inflammatory assay for the EtOAc extract 
from P. insignis shell incorporated in formulations F1 and 
F2 are shown in Figure 4.
The Tukey’s post-test evidenced that the fruit extract 
incorporated in the formulations F1 and F2 significantly 
reduces paw edema when compared to the untreated 
group. Compared with the group receiving dexamethasone 
(positive control), a similar reduction was observed between 
the groups.
After 6 h of treatment, the anti-inflammatory effect 
was observed for the group treated with dexamethasone, 
reducing in 27.4% of the animals’ paw edema. In the groups 
consisting in animals treated with the water solubilized 
extract, extract incorporated in F1 and extract incorporated 
in F2, the percentages of decrease of the edema were 
29.2, 31.0, and 24.1%, respectively, evidencing a greater 
inhibition of edema when treatment occurs with the extract 
incorporated into formulation F1.
It is most likely that the greater reduction of edema in 
the group treated with the extract incorporated in F1 is due 
to the behavior of phase and viscosity of the crystalline 
liquid that can affect both the release of the extract and the 
skin permeation since, in general, formulations with higher 
viscosity lead to a slow release of the active principle. Similar 
results of reduction of paw edema have been reported in the 
literature by da Silva et al.56 and Fonseca-Santos et al.57 that 
used LCS with procetyl as a surfactant as well.
In vivo anti-inflammatory assays have already been 
reported for morelloflavone by Otuki et al.,50 however, 
this is the first time that this approach was applied for the 
evaluation of this activity in an extract containing a high 
amount of this compound.
The results obtained in the in vitro and in vivo anti-
inflammatory assays are contradictory. The in vitro 
Figure 4. Anti-inflammatory activity results obtained for dexamethasone (positive control) at 1 mg g−1, solubilized extract at 400 µg mL−1, formulation 
F1, formulation F2, extract incorporated to F1 at 400 µg g−1, extract incorporated to F2 at 400 µg g−1 and negative control (not treated). Data are presented 
as mean ± standard deviation of the results of five mice. The statistical significance of paw edema was analyzed using analysis of variance by Tukey’s 
multiple comparison test; ****p < 0.05.
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experiment with the extract did not show activity, while 
during the in vivo assay it was able to reduce paw edema 
by up to 31%. These results show that one of the abiding 
weaknesses of in vitro experiments is that, sometimes, they 
might not be effective in replicating the precise cellular 
conditions of an organism.
Conclusions
This research provides a study of the chemical 
composition and biological activities of the Platonia insignis 
seeds and shell extracts. The results showed that the high 
antioxidant and anti-glycant activities present in the shell 
of bacuri can be attributed to the high concentration of the 
biflavonoid morelloflavone. Although four biflavonoids 
were identified in the seeds extract, it presented less 
pronounced bioactivities, being still important since this 
class of compounds is recognized for its antioxidant 
potential that can attribute high added value to the residues 
of the fruit. It is also possible to state that this residue can 
be used commercially as raw material for several sectors 
since its EtOAc extract obtained has extracted selectively 
an important biflavonoid. Finally, it was observed the 
maintenance of the biological activity of the extract 
incorporated into the drug carrier system, an important 
characteristic that can guarantee industrial and biomedical 
applicability to this residue for the treatment of several 
diseases.
Supplementary Information
S u p p l e m e n t a r y  i n f o r m a t i o n  ( H P L C - DA D 
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